Azelastine nasal spray significantly reduces SARS-CoV-2 infections in clinical trial

Sanatate

Saarland University Sep 2 2025 The trial, led by Professor Robert Bals, Director of the Department of Internal Medicine V at Saarland University Medical Center and Professor of Internal Medicine at Saarland University, divided the 450 participants into two groups. The treatment group of 227 individuals used an azelastine nasal spray three times a day over a 56-day period. During that same period, the 223 participants in the control group used a placebo spray three times a day. Robert Bals

din zilele anterioare